Parabilis director granted 20,215 stock options

Parabilis Medicines, Inc. director Jake Simson received a stock option grant covering 20,215 shares of common stock.

Accepted by SEC EDGAR 06/11/2026 - 04:47 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Parabilis Medicines, Inc. director Jake Simson received a stock option grant covering 20,215 shares of common stock. The option has a conversion price of $20.00 per share and expires on June 8, 2036.

The option vests and becomes exercisable in full on the earlier of June 9, 2027 or the date of the company’s next annual stockholder meeting, as long as Simson continues to serve on the board through that vesting date. After this award, he holds 20,215 option-derived shares directly.

Insider Trade Summary

Grant/Award: 20,215 shares

Grant/Award 1 txn

Insider Simson Jake

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	20,215	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 20,215 contracts (Direct)

Holdings Before and After: Stock Option (Right to Buy), 0 to 20,215 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 9, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Key Figures

Option grant size: 20,215 shares Exercise price: $20.00 per share Shares after transaction: 20,215 shares +2 more

5 metrics

Option grant size 20,215 shares Underlying common stock in new option award

Exercise price $20.00 per share Conversion or exercise price of the option

Shares after transaction 20,215 shares Total option-derived shares following the grant

Expiration date June 8, 2036 Option expiration for this grant

Vesting latest date June 9, 2027 Latest date when options vest if still serving

Key Terms

Stock Option (Right to Buy), conversion or exercise price, expiration date, vest and become exercisable

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

conversion or exercise price financial

"conversion_or_exercise_price: "20.0000""

expiration date financial

"expiration_date: "2036-06-08T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest and become exercisable financial

"shall vest and become exercisable in full upon the earlier of"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Parabilis Medicines (PBLS) director Jake Simson report on this Form 4?

Jake Simson reported receiving a grant of stock options covering 20,215 shares of Parabilis Medicines common stock. The award is a compensation-related grant with a $20.00 exercise price, not an open-market purchase or sale of existing PBLS shares.

How many Parabilis Medicines (PBLS) options did Jake Simson receive and at what price?

He received stock options for 20,215 underlying PBLS common shares at a $20.00 per share exercise price. This means he can buy those shares at $20.00 once the options vest and become exercisable, subject to the vesting conditions being met.

When do Jake Simson’s Parabilis Medicines (PBLS) stock options vest?

The options vest in full on the earlier of June 9, 2027 or the date of Parabilis Medicines’ next annual stockholders’ meeting. Vesting requires that Simson continue serving as a director through that vesting date, according to the footnote disclosure.

When do Jake Simson’s Parabilis Medicines (PBLS) options expire?

The stock options expire on June 8, 2036 if not exercised. After that expiration date, Simson would no longer be able to purchase PBLS shares at the $20.00 exercise price provided by this particular grant of options.

Is Jake Simson’s Form 4 for Parabilis Medicines (PBLS) a buy or a sale of shares?

The Form 4 reports an option grant acquisition, not a market buy or sale. Code “A” reflects a grant or award of derivative securities as compensation, so there is no open-market purchase or disposition of existing PBLS common stock in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simson Jake

(Last) (First) (Middle)

C/O PARABILIS MEDICINES, INC.

30 ACORN PARK DRIVE, 6TH FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02140

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Parabilis Medicines, Inc. [ PBLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$20	06/09/2026		A		20,215		(1)	06/08/2036	Common Stock	20,215	$0.00	20,215	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 9, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

	/s/ Teresa Jurgensen, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)